Insilico still feels the need for TEAD
Other new first-in-human trials involve CD74, where Gilead and Sutro tried and failed, and the emerging target MAT2A.
The month ahead: August’s remaining events
Following its odronextamab knockback, Regeneron now faces a delay to linvoseltamab.
Ideaya socks it to GSK
Two years after being snubbed by GSK, Ideaya shows the promise of MAT2A inhibition.
Servier completes its retreat from cell therapy
The sale of remaining rights to Allogene ends acrimony between the two companies.
FDA critics barely lay a glove on Geron
Imetelstat appears headed for approval after its US adcom turns into a damp squib.
Novartis calls time on TIM-3 and HIF2α
The company’s move could be a warning for rivals including GSK, AstraZeneca and Incyte.
New phase 1 projects enter hot fields
Analysis of industry assets newly into human trials reveals three Car-T therapies and some familiar targets.
Cellectis gets another bailout
Nine years after a groundbreaking deal with Pfizer, Cellectis goes to AstraZeneca for a fresh lease of life.
